Delving into the Latest Updates on Pfizer AB with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

ER x PR	1

关联

1

项与 Pfizer AB 相关的药物

Estradiol/Trimegestone

雌二醇/曲美孕酮

靶点

ER x PR

作用机制

ERs激动剂 [+1]

在研机构

Pfizer Inc. [+1]

原研机构

Sanofi

在研适应症

更年期综合症 [+2]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

瑞典

首次获批日期2000-01-01

4

项与 Pfizer AB 相关的临床试验

EUCTR2004-001378-19-SE

/ Not yet recruitingN/A

A two part study to a) investigate the reproducilibility of the vaginal photoplethysmograhpy (VPP) teqnique in healthy pre-menopausal volunteers and subjects suffering from Female Sexual Arousal Disorder (FSAD) and b) a randomised double blind, placebo conrolled 4-way crossover study to investigate the effect of single oral doses (10, 50 and 400 mg)of UK-447,841 on vaginal blood flow in pre-menopausal subjects suffering from FSAD. - N/A

开始日期2004-09-28

申办/合作机构

Pfizer AB

EUCTR2004-001379-20-SE

/ Not yet recruitingN/A

A two part study to a) investigate the reproducibility of the vaginal photoplethysmography (VPP) technique in healthy post-menopausal volunteers and subjects suffering from Female Sexual Arousal Disorder (FSAD) and b) a randomised double blind, placebo controlled 4-way crossover study to investigate the effect of single oral doses (10, 50 and 400mg) of UK-447,841 on vaginal blood flow in post-menopausal subjects suffering from FSAD. - N/A

开始日期2004-09-28

申办/合作机构

Pfizer AB

EUCTR2004-000139-27-SE

/ Not yet recruitingN/A

A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo, in Subjects With Mixed Dyslipidemia (Frederickson Types IIa and IIb). - N/A

开始日期2004-09-14

申办/合作机构

Pfizer AB

100 项与 Pfizer AB 相关的临床结果

登录后查看更多信息

0 项与 Pfizer AB 相关的专利（医药）

登录后查看更多信息

1

项与 Pfizer AB 相关的新闻（医药）

2023-10-19

·Endpoints

Illinois man accused of insider trading after making nearly $100K on Pfizer-Array buyout

A suburban Chicago man who used insider information he got from his spouse, who worked at Array BioPharma, to make nearly $100,000 from buying and selling stock options will now face charges in a federal court, according to government documents. The spouse and companies involved are unnamed by the US Attorney’s Office for the Northern District of Illinois, which put out a press release Wednesday, and in court records. But a release and complaint from the SEC specified the allegations: The “suburban Chicago man,” Brian Rubin, is facing accusations of buying stock options in Array before it was announced that it would be acquired by Pfizer for $11.4 billion in June 2019.

并购专利侵权

100 项与 Pfizer AB 相关的药物交易

登录后查看更多信息

100 项与 Pfizer AB 相关的转化医学

登录后查看更多信息